ABSTRACT
CASO CLÍNICO: Mujer de 73 años en tratamiento con escitalopram que presentó glaucoma agudo de ángulo cerrado secundario a efusión uveal tras duplicar la dosis de dicho fármaco 3 días antes. Evolucionó favorablemente tras la suspensión del antidepresivo además de tratamiento hipotensor tópico y prednisona vía oral. DISCUSIÓN: La efusión uveal secundaria a fármacos es un síndrome infrecuente. Se puede acompañar de miopización y glaucoma agudo por cierre angular. El diagnóstico correcto y la suspensión del fármaco conducen a la resolución de esta nosología
CASE REPORT: A 73 year-old woman with depression treated with escitalopram developed acute secondary angle closure glaucoma related to uveal effusion after duplicating the drug dose 3 days before. She evolved favorably once the antidepressant treatment was suspended and a new treatment with topical hypotensive therapy and oral prednisone was used. DISCUSSION: The uveal effusion syndrome associated to medicines is rare; it may be associated with acute myopic shift and acute angle closure glaucoma. The correct diagnosis and discontinuation of the drug lead to the resolution of this nosology
Subject(s)
Adult , Female , Humans , Uveal Diseases/chemically induced , Antidepressive Agents/adverse effects , Myopia/chemically induced , Glaucoma/chemically induced , Headache/etiologyABSTRACT
CASE REPORT: A 73 year-old woman with depression treated with escitalopram developed acute secondary angle closure glaucoma related to uveal effusion after duplicating the drug dose 3 days before. She evolved favorably once the antidepressant treatment was suspended and a new treatment with topical hypotensive therapy and oral prednisone was used. DISCUSSION: The uveal effusion syndrome associated to medicines is rare; it may be associated with acute myopic shift and acute angle closure glaucoma. The correct diagnosis and discontinuation of the drug lead to the resolution of this nosology.
Subject(s)
Citalopram/adverse effects , Glaucoma, Angle-Closure/chemically induced , Selective Serotonin Reuptake Inhibitors/adverse effects , Subretinal Fluid , Uveal Diseases/chemically induced , Acute Disease , Aged , Atropine/therapeutic use , Brimonidine Tartrate/therapeutic use , Choroid Diseases/chemically induced , Choroid Diseases/drug therapy , Ciliary Body/pathology , Drug Overdose , Emergencies , Female , Glaucoma, Angle-Closure/drug therapy , Humans , Myopia/chemically induced , Prednisone/therapeutic use , Receptors, Serotonin/drug effects , Receptors, Serotonin/physiology , Subretinal Fluid/diagnostic imaging , Timolol/therapeutic use , Uveal Diseases/drug therapy , Uveal Diseases/physiopathologyABSTRACT
Caso clínico: Mujer de 64 años en tratamiento con amantadina durante 2 años por enfermedad de Parkinson, que presentó edema corneal bilateral de inicio brusco. Inicialmente se trató como una endotelitis herpética sin mejoría, al desconocer la medicación empleada por la enferma. Finalmente el edema se resolvió tras la suspensión del fármaco. Discusión: El hidrocloruro de amantadina puede producir disfunción endotelial. El edema corneal puede ser reversible tras su suspensión, pero la densidad endotelial permanece baja. Sería necesario realizar un control oftalmológico previo al inicio del tratamiento para valorar el riesgo/beneficio del mismo, sobre todo en los pacientes que presenten baja densidad endotelial o un endotelio alterado (AU)
Case report: A 64 year-old female with Parkinson disease treated with amantadine for two years who suddenly suffered bilateral corneal oedema. It was initially treated as herpetic endotheliitis without improvement as we lacked information on her chronic treatment. The corneal oedema finally resolved after withdrawing the drug. Discussion: Amantadine hydrochloride may produce endothelial dysfunction. Once the amantadine treatment is stopped, the corneal oedema may be reversible but endothelial density remains low. An ophthalmologist examination should be performed before the initiation of amantadine treatment in order to establish a risk: benefit ratio, especially in those patients with low endothelial density or any endothelial anomaly (AU)
Subject(s)
Humans , Female , Aged , Amantadine/adverse effects , Amantadine/pharmacology , Amantadine/therapeutic use , Corneal Edema , Case ReportsABSTRACT
CASE REPORT: A 64 year-old female with Parkinson disease treated with amantadine for two years who suddenly suffered bilateral corneal oedema. It was initially treated as herpetic endotheliitis without improvement as we lacked information on her chronic treatment. The corneal oedema finally resolved after withdrawing the drug. DISCUSSION: Amantadine hydrochloride may produce endothelial dysfunction. Once the amantadine treatment is stopped, the corneal oedema may be reversible but endothelial density remains low. An ophthalmologist examination should be performed before the initiation of amantadine treatment in order to establish a risk: benefit ratio, especially in those patients with low endothelial density or any endothelial anomaly.
